Last reviewed · How we verify
Week 60
This drug targets the PD-1 receptor to inhibit cancer cell growth.
This drug targets the PD-1 receptor to inhibit cancer cell growth. Used for Non-small cell lung cancer, PD-L1 positive, Melanoma.
At a glance
| Generic name | Week 60 |
|---|---|
| Sponsor | University Hospital, Ghent |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, the drug prevents cancer cells from evading the immune system, allowing the body's immune cells to attack and destroy the cancer cells. This leads to an anti-tumor response and potentially prolonged survival in patients with certain types of cancer.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Melanoma
Common side effects
- Pneumonitis
- Hypothyroidism
- Diarrhea
- Fatigue
- Nausea
- Rash
- Pruritus
- Arthralgia
- Myalgia
- Headache
Key clinical trials
- The Effect of NP-2006 on Sleep Quality and Health (NA)
- Comparison of the Effects of Free Weight and Machine-Based Exercises on Muscular Parameters (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- The Effectiveness of Neurodevelopmental Treatment (Bobath) and Functional Physiotherapy in Children With Cerebral Palsy. (NA)
- Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors (NA)
- Reducing Symptom Burden Through Physical Exercise in Melanoma Patients (NA)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Week 60 CI brief — competitive landscape report
- Week 60 updates RSS · CI watch RSS
- University Hospital, Ghent portfolio CI